Big pharma against CL move but WHO agrees


Right to get treatment: It was reported last year that there were 400,000 Hepatitis C sufferers in Malaysia, with only a fraction who could afford the RM300,000 cost. — AFP

KUALA LUMPUR: Malaysia’s bold move to impose compulsory licence (CL) on the drug sofosbuvir has been heavily criticised by big pharmaceutical companies, but has the support of the World Health Organisation (WHO).

WHO advocates universal health coverage and that means access to life-saving treatment, said its head of mission and representative to Malaysia, Brunei and Singapore Dr Lo Ying-Ru.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Nation

Two local men arrested over firebombing of entertainment outlet in Jalan Yap Kwan Seng
Entrepreneur Development Minister urges Sabahans to register as Co-opbank Pertama members
KKB polls: Go out to vote with peace of mind as safety assured, says s'gor police
Malaysia ready to strengthen ties with S'pore under incoming PM, Lawrence Wong, says Anwar
Teacher from Melaka pleads not guilty to sexual assault in Sabah
KKB polls: Voter turnout to determine winner, says Ilham Centre
Syed Saddiq applies for temporary release of passport to go to Singapore and Taiwan
Family of man killed in tree-falling incident to get Socso benefits, says Sim
Lahad Datu water surge victims’ family get donations from DPM Zahid
Mutang to be laid to rest in Miri on May 13

Others Also Read